Objectives Remission (REM) or low disease activity (LDA) is the treatment target in psoriatic arthritis (PsA). The objective of this study was to assess the reporting and prevalence of REM/LDA in published studies of PsA. Methods This was a systematic literature review of all clinical papers published in PubMed, EMBASE or Cochrane database in English between 2012 and 2019 in the field of PsA. Data were collected regarding reporting of REM/LDA by very low disease activity/minimal disease activity (VLDA/MDA), Disease Activity index for Psoriatic Arthritis (DAPSA), or Disease Activity Score 28 joints (DAS28). The pooled rates of REM and LDA by each definition were calculated by random effect meta-analysis. Results In all, 258 publications (corresponding to 114~651 patients), of which 81 (31%) were randomized controlled trials, were analysed: patients' mean age was 49.4\,(\,4.4)\,years; with a mean disease duration of 8.5\,(\,3.8)\,years. REM/LDA was reported in 91/258 (35.3%) publications. VLDA/MDA was used in 61/91 (67.0%) studies, DAPSA in 27/91 (29.6%) and DAS28 in 28/91 (30.7%), with 40/91 (43.9%) papers reporting several of these definitions. The pooled prevalence (lower\textendash upper limits) of REM was 13.1% (10.9\textendash 15.4), 23.1% (16.8\textendash 30.1) and 42.1% (33.9\textendash 50.4) using VLDA, DAPSA-REM and DAS28, respectively. For LDA the pooled prevalence was 36.3% (32.3\textendash 40.5), 52.8% (41.8\textendash 63.6) and 60.4% (52.5\textendash 68.0) using MDA, DAPSA-LDA and DAS28, respectively. Conclusion REM/LDA status was reported in only1/3 of recent studies on PsA, with important variations in the frequency of these outcomes according to the definition used: 13.1\textendash 42.1% for REM, and 36.3\textendash 60.4% for LDA. This highlights the need for consensus.